An observational study in Periodic Breathing, sponsored by Wissenschaftliches Institut Bethanien e.V. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Sleep Apnea Syndromes with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea Syndromes · Germany.
Among the 58 studies in Sleep Apnea Syndromes with a site in Germany, this one is the 27th largest by enrollment of the 29 observational ones that give a count, is one of 8 that started in 2016, is one of 29 observational ones, and was the 48th registered.
1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.
Browse Sleep Apnea Syndromes studies →4 of the 58 studies in Sleep Apnea Syndromes with a site in Germany are open now. Recruiting first, the newest first:
Inspire Medical Systems, Inc. · Sites in Germany, Austria, Belgium and 4 more countries
Ages 18+
Technische Universität Dresden · Sites in Germany
Ages 18+
Christina Berr. MD · Sites in Germany
Ages 18+
Johannes Gutenberg University Mainz · Sites in Germany
Ages 18–120
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2016.
This study's enrollment of 12 is below the median of 150 across 343 observational studies indexed under Sleep Apnea Syndromes.
Median enrollment 60 across the 29 interventional studies, 200 across the 29 observational. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 58 have an industry lead sponsor. The 10 most frequent:
Wissenschaftliches Institut Bethanien e.V is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Wissenschaftliches Institut Bethanien e.V has 4 studies filed under Sleep Apnea Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Sleep Apnea Syndromes with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Central sleep apnoea (CSA) is common in patients with chronic systolic heart failure (HFrEF). Various trials have shown a prevalence of 21 - 37% in this group of people. Up to 66% of patients with CSA and HFrEF present with periodic breathing (PB), which is considered being a marker of HF severity and poor prognosis. Brack et al. summarized data from cohorts, longitudinal studies and retrospective analyses showing an independently increased risk of death in HF patients with PB (HR 2.1-5.7 in five of seven studies). Furthermore, PB in HF patients is known to reduce quality of life and exercise performance and to increase sympathetic nerve activity as well as the probability of malignant cardiac arrhythmias.
The pathogenesis of PB is characterized by an instability of ventilatory drive. The level of carbon dioxide (CO2) in blood and cerebrospinal fluid correlates linearly with minute ventilation. A high level of CO2 increases ventilation while hypocapnia dampens it. This control theory is based on the loop gain (LG), which represents the sensitivity and reactivity of the ventilatory system and comprises three components: The plant gain defines the capacity of the system to change PaCO2 in response to a change in ventilation (metabolic response). It is influenced by the lung volume as well as the anatomy of the thorax and the upper airways. The feedback gain is defined by the chemoreceptor responsiveness in reaction to blood gas changes. The controller gain is represented by the respiratory control center in the brain stem and defines the capacity of the system to change ventilation in response to a change in PaCO2 (ventilatory response).
Sands et al. proposed and validated a mathematical model based on the ventilatory cycle pattern that quantifies the feedback loop. The ratio of ventilatory and cycle duration within the PB pattern is defined as the duty ratio (DR), which is the basis to calculate the LG. Any temporary breathing disturbance causing a PB pattern with a LG \< 1 stabilizes within a few breathing cycles. A LG > 1 represents an unstable ventilatory response and slight changes of CO2 are accompanied by overshooting and undershooting of the ventilation. In that case, the polysomnography shows the typical pattern of waxing and waning of the tidal volume and effort.
HF patients typically present with an increased LG due to an impaired left ventricular function and a hyperstimulation of pulmonary vagal receptors. Furthermore, Khoo showed an increased chemosensitivity (controller gain) as well as a decreased ventilatory capacity (plant gain) in this group of people.
Sands and colleagues characterized PB considering the mean LG derived from several ventilatory cycles during non-REM sleep. This retrospective study of PB in HFrEF patients addresses the following questions:
Patients admitted to the sleep lab for diagnostic polysomnography.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Systolic heart failure with predominant central sleep apnea and periodic breathing
Loop Gain
Mathematically determined loop gain of periodic breathing according to Sands et al. \[10\] based on diagnostic polysomnography
Time frame: During one day of diagnostic polysomnography
Plan to share: No
Ran from Jun 2016 to primary completion in Nov 2016, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wissenschaftliches Institut Bethanien e.V